BIP-135
SIGMA/SML0265 - ≥95% (HPLC)
Synonym: 3-
CAS Number: 941575-71-9
Empirical Formula (Hill Notation): C21H13BrN2O3
Molecular Weight: 421.24
MDL Number: MFCD16495779
Linear Formula: C21H13BrN2O3
Product Type: Chemical
| assay | ≥95% (HPLC) |
| color | light orange to dark orange |
| form | powder |
| InChI | 1S/C21H13BrN2O3/c1-24-9-1 |
| InChI key | QKQJCKAXFJBYKJ-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | Cn1cc(C2=C(C(=O)NC2=O)c3c |
| solubility | DMSO: ≥15 mg/mL |
| storage temp. | room temp |
| Biochem/physiol Actions: | BIP-135 is a potent inhibitor of glycogen synthase kinase-3 (GSK3) found to be relatively selective for GSK-3β (21 nM) over GSK-3α with modest activity toward PKCβ (β1: 980 nM; β2: 219 nM), DYRK1B (590 nM), and PI3Kα (870 nM). BIP-135 was found to be a superior neuroprotective agent in a cortical neuron model of oxidative stress over other GSK-3 inhibitors, such as AR-A011418 and SB216763. In a mouse model of spinal muscular atrophy (SMA), BIP-135 elevated SMN protein levels in vitro and extended median survival. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P301 + P310 |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |